COVID-19: BRIEF REVIEW ON PATHOPHYSIOLOGY AND INVESTIGATIONAL DRUGS

Though coronaviruses are firstly recognized almost 6 decades back, but only reputed in 2003 and were identified that one of the members is served as the aetiologic vehicle for SARS (severe acute respiratory syndrome). Formerly coronaviruses are well-known as crucial pathogens for causing infections to ventilatory system nothing but respiratory system and enteric system nothing but digestive system of patients, causing common cold in 15z% cases of all cases. The coronaviruses are probably human pathogens accomplished with pathological signs in upper and lower respiratory tract. The virological studies particularly coronavirology has been remarkably developed from the last decade. Animal coronaviruses were enlightened during the SARS wide-spread and COVID-19 pandemic brought human coronaviruses (Novel coronavirus-2019) into the spotlight.On 7th July,2020 WHO technical lead head COVID-19 Dr Maria Van Kerkhove briefed the “evidence emerging” of the transmission of the COVID-19 through air. The potentiality of spread through air in public places particularly in closed, poorly ventilated, crowded places is high. Our review gives an account on investigational drugs and repurposed drugs that are being used for management and treatment of coronavirus disease (COVID-19) with their Id’s and mechanism of action against SARS-CoV-2 and data regarding current clinical investigations is also provided.